Covariate | Total No. (%) | Low AFP (%) | High AFP (%) | P |
---|---|---|---|---|
Total | 158 | 138 | 20 | Â |
Age | Â | Â | Â | Â |
< 60 | 54(34.2) | 48(34.8) | 6(30.0) | 0.673 |
≥ 60 | 104(65.8) | 90(65.2) | 14(70.0) |  |
Gender | Â | Â | Â | Â |
Male | 120(75.9) | 102(73.9) | 18(90.0) | 0.196 |
Female | 38(24.1) | 36(26.1) | 2(10.0) | Â |
ECOG PS | Â | Â | Â | Â |
0–1 | 92(58.2) | 83(60.1) | 9(45.0) | 0.199 |
2–3 | 66(41.8) | 55(39.9) | 11(55.0) |  |
CPS | Â | Â | Â | Â |
< 5 | 117(74.1) | 99(71.7) | 18(90.0) | 0.181 |
≥ 5 | 41(25.9) | 39(28.3) | 2(10.0) |  |
HER2 status | Â | Â | Â | Â |
Negative | 133(84.2) | 116(84.1) | 17(85.0) | 1.000 |
Positive | 25(15.8) | 22(15.9) | 3(15.0) | Â |
EBV status | Â | Â | Â | Â |
Negative | 144(91.1) | 124(89.9) | 20(100.0) | 0.284 |
Positive | 14(8.9) | 14(10.1) | 0(0.0) | Â |
Surgical history | Â | Â | Â | Â |
No | 110(69.6) | 95(68.8) | 15(75.0) | 0.576 |
Yes | 48(30.4) | 43(31.2) | 5(25.0) | Â |
TNM stage | Â | Â | Â | Â |
III | 55(34.8) | 51(37.0) | 4(20.0) | 0.137 |
IV | 103(65.2) | 87(63.0) | 16(80.0) | Â |
Treatment regimen | Â | Â | Â | Â |
ICI plus chemotherapy | 110(69.6) | 97(70.3) | 13(65.0) | 0.092 |
ICI plus targeted therapy | 18(11.4) | 13(9.4) | 5(25.0) | Â |
ICI plus chemotherapy and targeted therapy | 30(19.0) | 28(20.3) | 2(10.0) | Â |
Treatment lines | Â | Â | Â | Â |
1–2 | 138 (87.3) | 123(89.1) | 15(75.0) | 0.157 |
≥ 3 | 20(12.7) | 15(10.9) | 5(25.0) |  |
Liver metastases | Â | Â | Â | Â |
No | 116(73.4) | 106(76.8) | 10(50.0) | 0.011 |
Yes | 42(26.6) | 32(23.2) | 10(50.0) | Â |